BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 30943052)

  • 21. Incidence, clinicopathological features and outcome of primary central nervous system lymphomas. Population-based data from a Danish lymphoma registry. Danish Lymphoma Study Group, LYFO.
    Krogh-Jensen M; d'Amore F; Jensen MK; Christensen BE; Thorling K; Pedersen M; Johansen P; Boesen AM; Andersen E
    Ann Oncol; 1994 Apr; 5(4):349-54. PubMed ID: 8075032
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Primary central nervous system lymphoma.
    Stern JI; Raizer JJ
    Expert Rev Neurother; 2005 Nov; 5(6 Suppl):S63-70. PubMed ID: 16274272
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Primary CNS lymphoma at first relapse/progression: characteristics, management, and outcome of 256 patients from the French LOC network.
    Langner-Lemercier S; Houillier C; Soussain C; Ghesquières H; Chinot O; Taillandier L; Soubeyran P; Lamy T; Morschhauser F; Benouaich-Amiel A; Ahle G; Moles-Moreau MP; Moluçon-Chabrot C; Bourquard P; Damaj G; Jardin F; Larrieu D; Gyan E; Gressin R; Jaccard A; Choquet S; Brion A; Casasnovas O; Colin P; Reman O; Tempescul A; Marolleau JP; Fabbro M; Naudet F; Hoang-Xuan K; Houot R
    Neuro Oncol; 2016 Sep; 18(9):1297-303. PubMed ID: 26951382
    [TBL] [Abstract][Full Text] [Related]  

  • 24. TP53 hotspot mutations are predictive of survival in primary central nervous system lymphoma patients treated with combination chemotherapy.
    Munch-Petersen HD; Asmar F; Dimopoulos K; Areškevičiūtė A; Brown P; Girkov MS; Pedersen A; Sjö LD; Heegaard S; Broholm H; Kristensen LS; Ralfkiaer E; Grønbæk K
    Acta Neuropathol Commun; 2016 Apr; 4():40. PubMed ID: 27101868
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High-dose chemotherapy and autologous stem cell transplantation for primary central nervous system lymphoma: a multi-centre retrospective analysis from the United Kingdom.
    Kassam S; Chernucha E; O'Neill A; Hemmaway C; Cummins T; Montoto S; Lennard A; Adams G; Linton K; McKay P; Davies D; Rowntree C; Easdale S; Eyre TA; Marcus R; Cwynarski K; Fox CP
    Bone Marrow Transplant; 2017 Sep; 52(9):1268-1272. PubMed ID: 28581466
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Increasing incidence and continued dismal outcome of primary central nervous system lymphoma in Norway 1989-2003 : time trends in a 15-year national survey.
    Haldorsen IS; Krossnes BK; Aarseth JH; Scheie D; Johannesen TB; Mella O; Espeland A
    Cancer; 2007 Oct; 110(8):1803-14. PubMed ID: 17721992
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A single institutional retrospective evaluation for younger patients with primary central nervous lymphomas on a modified R-MPV regimen followed by radiotherapy and high dose cytarabine.
    Hattori K; Sakata-Yanagimoto M; Okoshi Y; Kato T; Kurita N; Yokoyama Y; Obara N; Takano S; Ishikawa E; Yamamoto T; Matsumura A; Hasegawa Y; Chiba S
    J Clin Exp Hematop; 2017 Oct; 57(2):41-46. PubMed ID: 28781291
    [TBL] [Abstract][Full Text] [Related]  

  • 28. White matter changes in primary central nervous system lymphoma patients treated with high-dose methotrexate with or without rituximab.
    Estephan F; Ye X; Dzaye O; Wagner-Johnston N; Swinnen L; Gladstone DE; Ambinder R; Kamson DO; Lambrecht S; Grossman SA; Lin DDM; Holdhoff M
    J Neurooncol; 2019 Dec; 145(3):461-466. PubMed ID: 31621040
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High-dose chemotherapy with thiotepa, busulfan, and cyclophosphamide and autologous stem cell transplantation for patients with primary central nervous system lymphoma in first complete remission.
    DeFilipp Z; Li S; El-Jawahri A; Armand P; Nayak L; Wang N; Batchelor TT; Chen YB
    Cancer; 2017 Aug; 123(16):3073-3079. PubMed ID: 28369839
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intravenous but not intrathecal central nervous system-directed chemotherapy improves survival in patients with testicular diffuse large B-cell lymphoma.
    Mannisto S; Vähämurto P; Pollari M; Clausen MR; Jyrkkiö S; Kellokumpu-Lehtinen PL; Kovanen P; Karjalainen-Lindsberg ML; d'Amore F; Leppä S
    Eur J Cancer; 2019 Jul; 115():27-36. PubMed ID: 31082690
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The elderly left behind-changes in survival trends of primary central nervous system lymphoma over the past 4 decades.
    Mendez JS; Ostrom QT; Gittleman H; Kruchko C; DeAngelis LM; Barnholtz-Sloan JS; Grommes C
    Neuro Oncol; 2018 Apr; 20(5):687-694. PubMed ID: 29036697
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of Primary Central Nervous System Lymphoma with High-dose Methotrexate and Radiotherapy in HIV-negative Patients.
    Jalaeikhoo H; Yekaninejad MS; Hajizamani S; Rahim F; Ahmadzadeh A; Keyhani M; Sadeghi Hariri B; Saki N
    Arch Iran Med; 2015 Sep; 18(9):577-81. PubMed ID: 26317598
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The influence of rituximab, high-dose therapy followed by autologous stem cell transplantation, and age in patients with primary CNS lymphoma.
    Madle M; Krämer I; Lehners N; Schwarzbich M; Wuchter P; Herfarth K; Egerer G; Ho AD; Witzens-Harig M
    Ann Hematol; 2015 Nov; 94(11):1853-7. PubMed ID: 26268792
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pretreatment dynamic contrast-enhanced MRI biomarkers correlate with progression-free survival in primary central nervous system lymphoma.
    Hatzoglou V; Oh JH; Buck O; Lin X; Lee M; Shukla-Dave A; Young RJ; Peck KK; Vachha B; Holodny AI; Grommes C
    J Neurooncol; 2018 Nov; 140(2):351-358. PubMed ID: 30073640
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial.
    Thiel E; Korfel A; Martus P; Kanz L; Griesinger F; Rauch M; Röth A; Hertenstein B; von Toll T; Hundsberger T; Mergenthaler HG; Leithäuser M; Birnbaum T; Fischer L; Jahnke K; Herrlinger U; Plasswilm L; Nägele T; Pietsch T; Bamberg M; Weller M
    Lancet Oncol; 2010 Nov; 11(11):1036-47. PubMed ID: 20970380
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Incidence, clinical features, treatment and outcome of primary central nervous system lymphoma in Norway.
    Salvesen Haldorsen I; Aarseth JH; Hollender A; Larsen JL; Espeland A; Mella O
    Acta Oncol; 2004; 43(6):520-9. PubMed ID: 15370608
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High-dose chemotherapy and autologous stem cell transplant compared with conventional chemotherapy for consolidation in newly diagnosed primary CNS lymphoma--a randomized phase III trial (MATRix).
    Schorb E; Finke J; Ferreri AJ; Ihorst G; Mikesch K; Kasenda B; Fritsch K; Fricker H; Burger E; Grishina O; Valk E; Zucca E; Illerhaus G
    BMC Cancer; 2016 Apr; 16():282. PubMed ID: 27098429
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High-dose thiotepa, busulfan, cyclophosphamide and ASCT without whole-brain radiotherapy for poor prognosis primary CNS lymphoma.
    Cheng T; Forsyth P; Chaudhry A; Morris D; Glück S; Russell JA; Stewart DA
    Bone Marrow Transplant; 2003 Apr; 31(8):679-85. PubMed ID: 12692608
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of rituximab in treatment of patients with primary central nervous system lymphoma: a retrospective analysis of the Czech lymphoma study group registry.
    Mocikova H; Pytlik R; Sykorova A; Janikova A; Prochazka V; Vokurka S; Berkova A; Belada D; Campr V; Buresova L; Trneny M;
    Leuk Lymphoma; 2016 Dec; 57(12):2777-2783. PubMed ID: 27087066
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [The clinical analysis of primary central nervous system lymphoma in 23 patients].
    Piao YZ; Li P; Liu Q; Li WL
    Zhonghua Nei Ke Za Zhi; 2011 Nov; 50(11):954-7. PubMed ID: 22333130
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.